Latest Johnson & Johnson News & Updates

See the latest news and media coverage for J&J. We track all announcements, press releases, and industry mentions in real time, all in one place.

Johnson & Johnson (J&J)

Multinational healthcare company

jnj.com

Headquarters: New Brunswick, United States
Company type: Public company
Number of employees: 100,000+

Last updated Today

Latest news about Johnson & Johnson (J&J)

In short: J&J advanced its oncology pipeline and expanded its MedTech portfolio while facing mixed outcomes in ongoing talc-related litigation.

Company announcements

June 19 J&J

J&J highlights positive MEMBRANE trial results in JAMA Neurology

The study showed MMA embolization with TRUFILL n-BCA reduced chronic subdural hematoma recurrence by 47% versus standard of care.

June 15 J&J

J&J invests over $1 billion in Jacksonville vision manufacturing

The investment includes new manufacturing and packaging technologies and a state-of-the-art distribution center to scale U.S. Vision operations, enhancing supply chain resilience for over 40 million patients.

June 13 J&J

J&J reports TALVEY plus DARZALEX FASPRO improves survival

Phase 3 MonumenTAL-3 shows up to 72% reduction in progression or death, with 24-month PFS up to 81% and OS up to 89%.

June 11 J&J

J&J's IMAAVY shows durable hemoglobin response in wAIHA study

The Phase 2/3 ENERGY trial met primary endpoint with rapid onset. No FDA-approved therapies exist for this condition.

Media coverage

June 21 Seeking Alpha

Healthcare headlines highlight Merck, Moderna, and Biogen

XLV falls as Moderna surges; CMS drug-price rule pressures Merck and J&J; Lilly and Biogen announce deals.

June 19 Insider Monkey

Johnson & Johnson’s Erleada Cuts Risk of Cancer Spread or Death by 20%, Reuters Reports - Insider Monkey

On May 31, Reuters reported that Johnson & Johnson (NYSE:JNJ)’s prostate cancer drug Erleada, when used alongside hormone-blocking therapy for six months before and after...

June 17 Bloomberg

J&J Passes on Obesity Drugs for Cancer

CEO Joaquin Duato says J&J will focus on cancer and other serious diseases instead of obesity drugs.

June 17 Tech Times

Johnson Johnson Myeloma Data Cuts Death Risk 53%: Cure Within Decade Gains Ground

Johnson Johnson cancer treatment strategy advanced this week as Phase 3 MonumenTAL-3 data showed TALVEY cuts myeloma death risk 53%, while a $1B bet on...

Never miss news about J&J

Track J&J and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

J&J competitors & trending companies

Browse news for competitors to J&J and other trending companies.